Genomic prediction of risk for biochemical relapse post-surgery

Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. … READ MORE …

Sexual rehabilitation after surgical treatment for localized prostate cancer: nine formal recommendations

Two recent articles by Salonia et al. (from the Fourth International Consultation for Sexual Medicine or ICSM 2015) have provided us with a series of nine recommendations to clinicians regarding sexual rehabilitation after radical prostatectomy for localized prostate cancer. … READ MORE …

Aggressive, neoadjuvant androgen ablation prior to surgery in higher risk prostate cancer patients

The development of drugs like abiraterone acetate and enzalutamide has stimulated new research into the use of such agents early on, in combination with first-line therapy, to see if it can affect the outcomes for men with high-risk and unfavorable intermediate-risk prostate cancer. … READ MORE …

Letters to the Editor on interpretation of data from the ProtecT trial

In September last year, Hamdy et al. published the initial results of the ProtecT trial — a trial designed to compare overall outcomes at 10 years among > 1,600 men diagnosed with low- and intermediate-risk, localized prostate cancer and randomized to treatment by surgery, by external beam radiation therapy, or by active monitoring (a very basic form of active surveillance). … READ MORE …

What you can’t prove can still be presented as if it were the truth

Another new article (this time in the journal JAMA Surgery) has tried to draw links between the USPSTF guidance on prostate cancer screening and a decrease in the numbers of men being referred to urologists for prostate biopsies and radical prostatectomies. … READ MORE …

Outcomes of 55 men who had prophylactic RALPs for suspicion of unproven prostate cancer

Over the years, we have been asked several times whether there is a role for any type of  immediate treatment in men with a high level of concern for their risk of prostate cancer — despite a negative finding on prostate biopsy. … READ MORE …

The initial (10-year) results of the ProtecT trial: much as we might have expected?

So the majority of the readers of The “New” Prostate Cancer InfoLink will be well aware that we have never had data from a large, randomized clinical trial comparing the outcomes of the commonest first-line forms of management of men diagnosed with localized prostate cancer … READ MORE …